Please select the option that best describes you:
Is the increase in RFS seen with adjuvant atezo/bev in IMbrave050 enough to change practice in resected HCC?
Answer from: Medical Oncologist at Academic Institution
The IMbrave050 showed that the combination atezolizumab/bevacizumab improved recurrence free survival in high risk resected HCC patients with RFS 78% vs 65% at 12 months, HR 0.72 (95% CI 0.56, 0.93), this tapered off at approximately 24 months. This suggests that the combination delayed recurrence a...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Not convinced based on this early report. I will wait to see longer RFS results given curved coming together and small benefits (borderline significant). OS is the real metric we need to see here.
Answer from: Medical Oncologist at Academic Institution
Completely agree with my colleagues. The benefit reported so far has been modest, and I'd need to see longer-term follow-up to change my practice, particularly given we will be expending an active regimen in the recurrent/advanced setting.
Answer from: Medical Oncologist at Academic Institution
The phase 3 randomized adjuvant Atezo/Bev IMbrave050 study (Hack et al., PMID 32352320) in HCC reached its primary endpoint of improving recurrence free survival and once approved by regulatory bodies based on their current data review in the US and globally, it will set a new standard of care optio...